Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiology and Therapy
Published in: Cardiology and Therapy 2/2020

Open Access 01-12-2020 | Aortic Valve Replacement | Review

Expansion of TAVR into Low-Risk Patients and Who to Consider for SAVR

Authors: Kunal V. Patel, Wally Omar, Pedro Engel Gonzalez, Michael E. Jessen, Lynn Huffman, Dharam J. Kumbhani, Anthony A. Bavry

Published in: Cardiology and Therapy | Issue 2/2020

Login to get access

Abstract

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of severe aortic stenosis (AS) over the last decade. The results of the Placement of Aortic Transcatheter Valves (PARTNER) 3 and Evolut Low Risk trials demonstrated the safety and efficacy of TAVR in low-surgical-risk patients and led to the approval of TAVR for use across the risk spectrum. Heart teams around the world will now be faced with evaluating a deluge of younger, healthier patients with severe AS. Prior to the PARTNER 3 and Evolut Low Risk studies, this heterogenous patient population would have undergone surgical aortic valve replacement (SAVR). It is unlikely that TAVR will completely supplant SAVR for the treatment of severe AS in patients with a low surgical risk, as SAVR has excellent short- and long-term outcomes and years of durability data. In this review, we outline the critical role that SAVR will continue to play in the treatment of severe AS in the post-PARTNER 3/Evolut Low Risk era.
Literature
1.
Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370(19):1790–8.PubMed
2.
Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187–98.PubMed
3.
Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374(17):1609–20.PubMed
4.
Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376(14):1321–31.PubMed
5.
Thourani VH, Suri RM, Gunter RL, Sheng S, O’Brien SM, Ailawadi G, et al. Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 low-risk, intermediate-risk, and high-risk patients. Ann Thorac Surg. 2015;99(1):55–61.PubMed
6.
Otto CM, Kumbhani DJ, Alexander KP, Calhoon JH, Desai MY, Kaul S, et al. 2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2017;69(10):1313–46.PubMed
7.
Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695–705.PubMed
8.
Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706–15.PubMed
9.
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(22):2438–88.PubMed
10.
Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation. 2005;111(7):920–5.PubMed
11.
Kong WKF, Delgado V, Bax JJ. Bicuspid aortic valve: what to image in patients considered for transcatheter aortic valve replacement? Circ Cardiovasc Imaging. 2017;10(9):e005987.PubMed
12.
Scharfschwerdt M, Meyer-Saraei R, Schmidtke C, Sievers HH. Hemodynamics of the Edwards Sapien XT transcatheter heart valve in noncircular aortic annuli. J Thorac Cardiovasc Surg. 2014;148(1):126–32.PubMed
13.
Sievers HH, Schmidtke C. A classification system for the bicuspid aortic valve from 304 surgical specimens. J Thorac Cardiovasc Surg. 2007;133(5):1226–33.PubMed
14.
Tchetche D, de Biase C, van Gils L, Parma R, Ochala A, Lefevre T, et al. Bicuspid aortic valve anatomy and relationship with devices: the BAVARD Multicenter Registry. Circ Cardiovasc Interv. 2019;12(1):e007107.PubMed
15.
Kanjanahattakij N, Horn B, Vutthikraivit W, Biso SM, Ziccardi MR, Lu MLR, et al. Comparing outcomes after transcatheter aortic valve replacement in patients with stenotic bicuspid and tricuspid aortic valve: a systematic review and meta-analysis. Clin Cardiol. 2018;41(7):896–902.PubMedPubMedCentral
16.
Yoon SH, Bleiziffer S, De Backer O, Delgado V, Arai T, Ziegelmueller J, et al. Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis. J Am Coll Cardiol. 2017;69(21):2579–89.PubMed
17.
Halim SA, Edwards FH, Dai D, Li Z, Mack MJ, Holmes DR, et al. Outcomes of transcatheter aortic valve replacement in patients with bicuspid aortic valve disease: a report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Circulation. 2020;141(13):1071–9.PubMed
18.
Makkar RR, Yoon SH, Leon MB, Chakravarty T, Rinaldi M, Shah PB, et al. Association between transcatheter aortic valve replacement for bicuspid vs tricuspid aortic stenosis and mortality or stroke. JAMA. 2019;321(22):2193–202.PubMedPubMedCentral
19.
Yoon SH, Lefevre T, Ahn JM, Perlman GY, Dvir D, Latib A, et al. Transcatheter aortic valve replacement with early- and new-generation devices in bicuspid aortic valve stenosis. J Am Coll Cardiol. 2016;68(11):1195–205.PubMed
20.
Elbadawi A, Saad M, Elgendy IY, Barssoum K, Omer MA, Soliman A, et al. Temporal trends and outcomes of transcatheter versus surgical aortic valve replacement for bicuspid aortic valve stenosis. JACC Cardiovasc Interv. 2019;12(18):1811–22.PubMed
21.
Waksman R, Craig PE, Torguson R, Asch FM, Weissman G, Ruiz D, et al. Transcatheter aortic valve replacement in low-risk patients with symptomatic severe bicuspid aortic valve stenosis. JACC Cardiovasc Interv. 2020;13(9):1019–27.PubMed
22.
Accf/Aha/Aats/Acr/Asa/Sca/Scai/Sir/Sts/Svm Guidelines For The D, Management of Patients With Thoracic Aortic Disease Representative M, Hiratzka LF, Creager MA, Isselbacher EM, Svensson LG, et al. Surgery for aortic dilatation in patients with bicuspid aortic valves: a statement of clarification from the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016;133(7):680–6.
23.
Svensson LG, Kim KH, Blackstone EH, Rajeswaran J, Gillinov AM, Mihaljevic T, et al. Bicuspid aortic valve surgery with proactive ascending aorta repair. J Thorac Cardiovasc Surg. 2011;142(3):622–9, 9e1–3.
24.
Colombo A, Mangieri A. Surgery versus TAVR for bicuspid aortic valve disease: the time has come for a randomized study. JACC Cardiovasc Interv. 2020;13(9):1028–9.PubMed
25.
Kodali SK, Velagapudi P, Hahn RT, Abbott D, Leon MB. Valvular heart disease in patients ≥ 80 years of age. J Am Coll Cardiol. 2018;71(18):2058–72.PubMed
26.
Yoon SH, Schmidt T, Bleiziffer S, Schofer N, Fiorina C, Munoz-Garcia AJ, et al. Transcatheter aortic valve replacement in pure native aortic valve regurgitation. J Am Coll Cardiol. 2017;70(22):2752–63.PubMed
27.
Bahlmann E, Cramariuc D, Minners J, Lonnebakken MT, Ray S, Gohlke-Baerwolf C, et al. Small aortic root in aortic valve stenosis: clinical characteristics and prognostic implications. Eur Heart J Cardiovasc Imaging. 2017;18(4):404–12.PubMed
28.
Coutinho GF, Correia PM, Pauperio G, de Oliveira F, Antunes MJ. Aortic root enlargement does not increase the surgical risk and short-term patient outcome? Eur J Cardiothorac Surg. 2011;40(2):441–7.PubMed
29.
Kulik A, Al-Saigh M, Chan V, Masters RG, Bedard P, Lam BK, et al. Enlargement of the small aortic root during aortic valve replacement: is there a benefit? Ann Thorac Surg. 2008;85(1):94–100.PubMed
30.
Mauri V, Kim WK, Abumayyaleh M, Walther T, Moellmann H, Schaefer U, et al. Short-term outcome and hemodynamic performance of next-generation self-expanding versus balloon-expandable transcatheter aortic valves in patients with small aortic annulus: a multicenter propensity-matched comparison. Circ Cardiovasc Interv. 2017;10(10):e005013.PubMed
31.
Freitas-Ferraz AB, Tirado-Conte G, Dagenais F, Ruel M, Al-Atassi T, Dumont E, et al. Aortic stenosis and small aortic annulus. Circulation. 2019;139(23):2685–702.PubMed
32.
Wagner IM, Eichinger WB, Bleiziffer S, Botzenhardt F, Gebauer I, Guenzinger R, et al. Influence of completely supra-annular placement of bioprostheses on exercise hemodynamics in patients with a small aortic annulus. J Thorac Cardiovasc Surg. 2007;133(5):1234–41.PubMed
33.
Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prosthesis–patient mismatch in the aortic valve position and its prevention. J Am Coll Cardiol. 2000;36(4):1131–41.PubMed
34.
Pibarot P, Dumesnil JG. Prosthesis–patient mismatch: definition, clinical impact, and prevention. Heart. 2006;92(8):1022–9.PubMed
35.
Dayan V, Vignolo G, Soca G, Paganini JJ, Brusich D, Pibarot P. Predictors and outcomes of prosthesis–patient mismatch after aortic valve replacement. JACC Cardiovasc Imaging. 2016;9(8):924–33.PubMed
36.
Fallon JM, DeSimone JP, Brennan JM, O’Brien S, Thibault DP, DiScipio AW, et al. The incidence and consequence of prosthesis–patient mismatch after surgical aortic valve replacement. Ann Thorac Surg. 2018;106(1):14–22.PubMed
37.
Clavel MA, Webb JG, Pibarot P, Altwegg L, Dumont E, Thompson C, et al. Comparison of the hemodynamic performance of percutaneous and surgical bioprostheses for the treatment of severe aortic stenosis. J Am Coll Cardiol. 2009;53(20):1883–91.PubMed
38.
Puri R, Byrne J, Muller R, Baumbach H, Eltchaninoff H, Redwood S, et al. Transcatheter aortic valve implantation in patients with small aortic annuli using a 20 mm balloon-expanding valve. Heart. 2017;103(2):148–53.PubMed
39.
Rodes-Cabau J, Pibarot P, Suri RM, Kodali S, Thourani VH, Szeto WY, et al. Impact of aortic annulus size on valve hemodynamics and clinical outcomes after transcatheter and surgical aortic valve replacement: insights from the PARTNER Trial. Circ Cardiovasc Interv. 2014;7(5):701–11.PubMed
40.
Pasic M, Unbehaun A, Buz S, Drews T, Hetzer R. Annular rupture during transcatheter aortic valve replacement: classification, pathophysiology, diagnostics, treatment approaches, and prevention. JACC Cardiovasc Interv. 2015;8(1 Pt A):1–9.PubMed
41.
Ribeiro HB, Nombela-Franco L, Urena M, Mok M, Pasian S, Doyle D, et al. Coronary obstruction following transcatheter aortic valve implantation: a systematic review. JACC Cardiovasc Interv. 2013;6(5):452–61.PubMed
42.
Castro LJ, Arcidi JM Jr, Fisher AL, Gaudiani VA. Routine enlargement of the small aortic root: a preventive strategy to minimize mismatch. Ann Thorac Surg. 2002;74(1):31–6 (Discussion 6).PubMed
43.
John D, Buellesfeld L, Yuecel S, Mueller R, Latsios G, Beucher H, et al. Correlation of Device landing zone calcification and acute procedural success in patients undergoing transcatheter aortic valve implantations with the self-expanding CoreValve prosthesis. JACC Cardiovasc Interv. 2010;3(2):233–43.PubMed
44.
Langer NB, Hamid NB, Nazif TM, Khalique OK, Vahl TP, White J, et al. Injuries to the aorta, aortic annulus, and left ventricle during transcatheter aortic valve replacement: management and outcomes. Circ Cardiovasc Interv. 2017;10(1):e004735.PubMed
45.
Barbanti M, Yang TH, Rodes Cabau J, Tamburino C, Wood DA, Jilaihawi H, et al. Anatomical and procedural features associated with aortic root rupture during balloon-expandable transcatheter aortic valve replacement. Circulation. 2013;128(3):244–53.PubMed
46.
Ewe SH, Ng AC, Schuijf JD, van der Kley F, Colli A, Palmen M, et al. Location and severity of aortic valve calcium and implications for aortic regurgitation after transcatheter aortic valve implantation. Am J Cardiol. 2011;108(10):1470–7.PubMed
47.
Koos R, Mahnken AH, Dohmen G, Brehmer K, Gunther RW, Autschbach R, et al. Association of aortic valve calcification severity with the degree of aortic regurgitation after transcatheter aortic valve implantation. Int J Cardiol. 2011;150(2):142–5.PubMed
48.
Pollari F, Dell’Aquila AM, Sohn C, Marianowicz J, Wiehofsky P, Schwab J, et al. Risk factors for paravalvular leak after transcatheter aortic valve replacement. J Thorac Cardiovasc Surg. 2019;157(4):1406–15 (e3).PubMed
49.
Pibarot P, Hahn RT, Weissman NJ, Arsenault M, Beaudoin J, Bernier M, et al. Association of paravalvular regurgitation with 1-year outcomes after transcatheter aortic valve replacement with the SAPIEN 3 valve. JAMA Cardiol. 2017;2(11):1208–16.PubMedPubMedCentral
50.
Thyregod HGH, Ihlemann N, Jorgensen TH, Nissen H, Kjeldsen BJ, Petursson P, et al. Five-year clinical and echocardiographic outcomes from the Nordic Aortic Valve Intervention (NOTION) randomized clinical trial in lower surgical risk patients. Circulation. 2019;139:2714–23.
51.
Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366(18):1686–95.PubMed
52.
Kapadia SR, Kodali S, Makkar R, Mehran R, Lazar RM, Zivadinov R, et al. Protection against cerebral embolism during transcatheter aortic valve replacement. J Am Coll Cardiol. 2017;69(4):367–77.PubMed
53.
Seeger J, Gonska B, Otto M, Rottbauer W, Wohrle J. Cerebral embolic protection during transcatheter aortic valve replacement significantly reduces death and stroke compared with unprotected procedures. JACC Cardiovasc Interv. 2017;10(22):2297–303.PubMed
54.
Nombela-Franco L, Rodes-Cabau J, DeLarochelliere R, Larose E, Doyle D, Villeneuve J, et al. Predictive factors, efficacy, and safety of balloon post-dilation after transcatheter aortic valve implantation with a balloon-expandable valve. JACC Cardiovasc Interv. 2012;5(5):499–512.PubMed
55.
Nombela-Franco L, Webb JG, de Jaegere PP, Toggweiler S, Nuis RJ, Dager AE, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation. 2012;126(25):3041–53.PubMed
56.
Beurtheret S, Karam N, Resseguier N, Houel R, Modine T, Folliguet T, et al. Femoral versus nonfemoral peripheral access for transcatheter aortic valve replacement. J Am Coll Cardiol. 2019;74(22):2728–39.PubMed
57.
Allen KB, Chhatriwalla AK, Cohen D, Saxon J, Hawa Z, Kennedy KF, et al. Transcarotid versus transapical and transaortic access for transcatheter aortic valve replacement. Ann Thorac Surg. 2019;108(3):715–22.PubMed
58.
Blackstone EH, Suri RM, Rajeswaran J, Babaliaros V, Douglas PS, Fearon WF, et al. Propensity-matched comparisons of clinical outcomes after transapical or transfemoral transcatheter aortic valve replacement: a placement of aortic transcatheter valves (PARTNER)-I trial substudy. Circulation. 2015;131(22):1989–2000.PubMed
59.
Chandrasekhar J, Hibbert B, Ruel M, Lam BK, Labinaz M, Glover C. Transfemoral vs non-transfemoral access for transcatheter aortic valve implantation: a systematic review and meta-analysis. Can J Cardiol. 2015;31(12):1427–38.PubMed
60.
Dahle TG, Kaneko T, McCabe JM. Outcomes following subclavian and axillary artery access for transcatheter aortic valve replacement: society of the thoracic surgeons/American College of Cardiology TVT Registry Report. JACC Cardiovasc Interv. 2019;12(7):662–9.PubMed
61.
Elmariah S, Fearon WF, Inglessis I, Vlahakes GJ, Lindman BR, Alu MC, et al. Transapical transcatheter aortic valve replacement is associated with increased cardiac mortality in patients with left ventricular dysfunction: insights from the PARTNER I trial. JACC Cardiovasc Interv. 2017;10(23):2414–22.PubMed
62.
Greenbaum AB, Babaliaros VC, Chen MY, Stine AM, Rogers T, O’Neill WW, et al. Transcaval access and closure for transcatheter aortic valve replacement: a prospective investigation. J Am Coll Cardiol. 2017;69(5):511–21.PubMed
63.
O’Hair DP, Bajwa TK, Popma JJ, Watson DR, Yakubov SJ, Adams DH, et al. Direct aortic access for transcatheter aortic valve replacement using a self-expanding device. Ann Thorac Surg. 2018;105(2):484–90.PubMed
64.
Di Mario C, Goodwin M, Ristalli F, Ravani M, Meucci F, Stolcova M, et al. A prospective registry of intravascular lithotripsy-enabled vascular access for transfemoral transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12(5):502–4.PubMed
65.
Palmerini T, Chakravarty T, Saia F, Bruno AG, Bacchi-Reggiani ML, Marrozzini C, et al. Coronary protection to prevent coronary obstruction during TAVR: a multicenter international registry. JACC Cardiovasc Interv. 2020;13(6):739–47.PubMed
66.
Khan JM, Greenbaum AB, Babaliaros VC, Rogers T, Eng MH, Paone G, et al. The BASILICA trial: prospective multicenter investigation of intentional leaflet laceration to prevent TAVR coronary obstruction. JACC Cardiovasc Interv. 2019;12(13):1240–52.PubMedPubMedCentral
67.
Rodes-Cabau J, Ellenbogen KA, Krahn AD, Latib A, Mack M, Mittal S, et al. Management of conduction disturbances associated with transcatheter aortic valve replacement: JACC scientific expert panel. J Am Coll Cardiol. 2019;74(8):1086–106.PubMed
68.
Thiele H, Kurz T, Feistritzer HJ, Stachel G, Hartung P, Eitel I, et al. Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial. Eur Heart J. 2020;41(20):1890–9.PubMed
69.
Nazif TM, Chen S, George I, Dizon JM, Hahn RT, Crowley A, et al. New-onset left bundle branch block after transcatheter aortic valve replacement is associated with adverse long-term clinical outcomes in intermediate-risk patients: an analysis from the PARTNER II trial. Eur Heart J. 2019;40(27):2218–27.PubMed
70.
Mouillet G, Lellouche N, Yamamoto M, Oguri A, Dubois-Rande JL, Van Belle E, et al. Outcomes following pacemaker implantation after transcatheter aortic valve implantation with CoreValve® devices: results from the FRANCE 2 Registry. Catheter Cardiovasc Interv. 2015;86(3):E158–66.PubMed
71.
Mauri V, Reimann A, Stern D, Scherner M, Kuhn E, Rudolph V, et al. Predictors of permanent pacemaker implantation after transcatheter aortic valve replacement with the SAPIEN 3. JACC Cardiovasc Interv. 2016;9(21):2200–9.PubMed
72.
Maeno Y, Abramowitz Y, Kawamori H, Kazuno Y, Kubo S, Takahashi N, et al. A Highly predictive risk model for pacemaker implantation after TAVR. JACC Cardiovasc Imaging. 2017;10(10 Pt A):1139–47.PubMed
73.
Gonska B, Seeger J, Kessler M, von Keil A, Rottbauer W, Wohrle J. Predictors for permanent pacemaker implantation in patients undergoing transfemoral aortic valve implantation with the Edwards Sapien 3 valve. Clin Res Cardiol. 2017;106(8):590–7.PubMed
74.
Nazif TM, Dizon JM, Hahn RT, Xu K, Babaliaros V, Douglas PS, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv. 2015;8(1 Pt A):60–9.PubMed
75.
Fadahunsi OO, Olowoyeye A, Ukaigwe A, Li Z, Vora AN, Vemulapalli S, et al. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement: analysis from the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry. JACC Cardiovasc Interv. 2016;9(21):2189–99.PubMed
76.
Aljabbary T, Qiu F, Masih S, Fang J, Elbaz-Greener G, Austin PC, et al. Association of clinical and economic outcomes with permanent pacemaker implantation after transcatheter aortic valve replacement. JAMA Netw Open. 2018;1(1):e180088.PubMedPubMedCentral
77.
Cerrato E, Nombela-Franco L, Nazif TM, Eltchaninoff H, Sondergaard L, Ribeiro HB, et al. Evaluation of current practices in transcatheter aortic valve implantation: the WRITTEN (WoRldwIde TAVI ExperieNce) survey. Int J Cardiol. 2017;228:640–7.PubMed
78.
Regueiro A, Abdul-Jawad Altisent O, Del Trigo M, Campelo-Parada F, Puri R, Urena M, et al. Impact of new-onset left bundle branch block and periprocedural permanent pacemaker implantation on clinical outcomes in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2016;9(5):e003635.PubMed
79.
Forrest JK, Kaple RK, Tang GHL, Yakubov SJ, Nazif TM, Williams MR, et al. Three generations of self-expanding transcatheter aortic valves: a report from the STS/ACC TVT registry. JACC Cardiovasc Interv. 2020;13(2):170–9.PubMed
80.
Nishimura RA, O’Gara PT, Bonow RO. Guidelines update on indications for transcatheter aortic valve replacement. JAMA Cardiol. 2017;2(9):1036–7.PubMed
81.
Goldstone AB, Chiu P, Baiocchi M, Lingala B, Patrick WL, Fischbein MP, et al. Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement. N Engl J Med. 2017;377(19):1847–57.PubMed
82.
Otto CM. Informed shared decisions for patients with aortic stenosis. N Engl J Med. 2019;380(18):1769–70.PubMed
83.
Rahimtoola SH. Choice of prosthetic heart valve in adults an update. J Am Coll Cardiol. 2010;55(22):2413–26.PubMed
84.
Chan V, Malas T, Lapierre H, Boodhwani M, Lam BK, Rubens FD, et al. Reoperation of left heart valve bioprostheses according to age at implantation. Circulation. 2011;124(11 Suppl):S75–80.PubMed
85.
Dvir D, Webb JG, Bleiziffer S, Pasic M, Waksman R, Kodali S, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA. 2014;312(2):162–70.PubMed
86.
Barbanti M, Costa G, Zappulla P, Todaro D, Picci A, Rapisarda G, et al. Incidence of long-term structural valve dysfunction and bioprosthetic valve failure after transcatheter aortic valve replacement. J Am Heart Assoc. 2018;7(15):e008440.PubMedPubMedCentral
87.
Sondergaard L, Ihlemann N, Capodanno D, Jorgensen TH, Nissen H, Kjeldsen BJ, et al. Durability of transcatheter and surgical bioprosthetic aortic valves in patients at lower surgical risk. J Am Coll Cardiol. 2019;73(5):546–53.PubMed
88.
Kumbhani DJ, Chhatriwalla AK. VIVID insights: tips for successful valve-in-valve TAVR in stented and stentless surgical valves. JACC Cardiovasc Interv. 2019;12(13):1264–7.PubMed
89.
Dvir D, Bourguignon T, Otto CM, Hahn RT, Rosenhek R, Webb JG, et al. Standardized definition of structural valve degeneration for surgical and transcatheter bioprosthetic aortic valves. Circulation. 2018;137(4):388–99.PubMed
90.
Capodanno D, Petronio AS, Prendergast B, Eltchaninoff H, Vahanian A, Modine T, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;38(45):3382–90.PubMed
91.
Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J. 2012;33(19):2403–18.PubMed
92.
Testa L, Latib A, Brambilla N, De Marco F, Fiorina C, Adamo M, et al. Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis. Eur Heart J. 2020;41:1876–86.PubMed
93.
Kataruka A, Otto CM. Valve durability after transcatheter aortic valve implantation. J Thorac Dis. 2018;10(Suppl 30):S3629–36.PubMedPubMedCentral
94.
Chakravarty T, Sondergaard L, Friedman J, De Backer O, Berman D, Kofoed KF, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389(10087):2383–92.PubMed
95.
Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, De Backer O, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373(21):2015–24.PubMed
96.
Waksman R, Rogers T, Torguson R, Gordon P, Ehsan A, Wilson SR, et al. Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis. J Am Coll Cardiol. 2018;72(18):2095–105.PubMed
97.
Tuzcu EM, Kapadia SR, Vemulapalli S, Carroll JD, Holmes DR Jr, Mack MJ, et al. Transcatheter aortic valve replacement of failed surgically implanted bioprostheses: the STS/ACC registry. J Am Coll Cardiol. 2018;72(4):370–82.PubMed
98.
Tam DY, Dharma C, Rocha RV, Ouzounian M, Wijeysundera HC, Austin PC, et al. Transcatheter ViV versus redo surgical AVR for the management of failed biological prosthesis: early and late outcomes in a propensity-matched cohort. JACC Cardiovasc Interv. 2020;13(6):765–74.PubMed
99.
Dauerman HL, Deeb GM, O’Hair DP, Waksman R, Yakubov SJ, Kleiman NS, et al. Durability and clinical outcomes of transcatheter aortic valve replacement for failed surgical bioprostheses. Circ Cardiovasc Interv. 2019;12(10):e008155.PubMed
100.
Deeb GM, Reardon MJ, Chetcuti S, Patel HJ, Grossman PM, Yakubov SJ, et al. 3-year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;67(22):2565–74.PubMed
101.
Webb JG, Mack MJ, White JM, Dvir D, Blanke P, Herrmann HC, et al. Transcatheter aortic valve implantation within degenerated aortic surgical bioprostheses: PARTNER 2 valve-in-valve registry. J Am Coll Cardiol. 2017;69(18):2253–62.PubMed
102.
Webb JG, Murdoch DJ, Alu MC, Cheung A, Crowley A, Dvir D, et al. 3-Year outcomes after valve-in-valve transcatheter aortic valve replacement for degenerated bioprostheses: the PARTNER 2 registry. J Am Coll Cardiol. 2019;73(21):2647–55.PubMed
103.
Aziz M, Simonato M, Webb JG, Abdel-Wahab M, McElhinney D, Duncan A, et al. Mortality prediction after transcatheter treatment of failed bioprosthetic aortic valves utilizing various international scoring systems: Insights from the Valve-in-Valve International Data (VIVID). Catheter Cardiovasc Interv. 2018;92(6):1163–70.PubMed
104.
Ejiofor JI, Yammine M, Harloff MT, McGurk S, Muehlschlegel JD, Shekar PS, et al. Reoperative surgical aortic valve replacement versus transcatheter valve-in-valve replacement for degenerated bioprosthetic aortic valves. Ann Thorac Surg. 2016;102(5):1452–8.PubMed
105.
Neupane S, Singh H, Lammer J, Othman H, Yamasaki H, Rosman HS, et al. Meta-analysis of transcatheter valve-in-valve implantation versus redo aortic valve surgery for bioprosthetic aortic valve dysfunction. Am J Cardiol. 2018;121(12):1593–600.PubMed
106.
Landes U, Webb JG, De Backer O, Sondergaard L, Abdel-Wahab M, Crusius L, et al. Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunction. J Am Coll Cardiol. 2020;75(16):1882–93.PubMed
107.
Goel SS, Ige M, Tuzcu EM, Ellis SG, Stewart WJ, Svensson LG, et al. Severe aortic stenosis and coronary artery disease–implications for management in the transcatheter aortic valve replacement era: a comprehensive review. J Am Coll Cardiol. 2013;62(1):1–10.PubMed
108.
Vilalta V, Asmarats L, Ferreira-Neto AN, Maes F, de Freitas Campos Guimaraes L, Couture T, et al. Incidence, clinical characteristics, and impact of acute coronary syndrome following transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11(24):2523–33.PubMed
109.
Tang GHL, Zaid S, Ahmad H, Undemir C, Lansman SL. Transcatheter valve neo-commissural overlap with coronary orifices after transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2018;11(10):e007263.PubMed
110.
Ochiai T, Yoon SH, Flint N, Sharma R, Chakravarty T, Kaewkes D, et al. Timing and outcomes of percutaneous coronary intervention in patients who underwent transcatheter aortic valve implantation. Am J Cardiol. 2020;125(9):1361–8.PubMed
111.
Arnold SV, Spertus JA, Vemulapalli S, Li Z, Matsouaka RA, Baron SJ, et al. Quality-of-life outcomes after transcatheter aortic valve replacement in an unselected population: a report from the STS/ACC transcatheter valve therapy registry. JAMA Cardiol. 2017;2(4):409–16.PubMedPubMedCentral
112.
Baron SJ, Arnold SV, Reynolds MR, Wang K, Deeb M, Reardon MJ, et al. Durability of quality of life benefits of transcatheter aortic valve replacement: Long-term results from the CoreValve US extreme risk trial. Am Heart J. 2017;194:39–48.PubMedPubMedCentral
113.
Reynolds MR, Magnuson EA, Wang K, Thourani VH, Williams M, Zajarias A, et al. Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). J Am Coll Cardiol. 2012;60(6):548–58.PubMed
114.
Hayashida K, Morice MC, Chevalier B, Hovasse T, Romano M, Garot P, et al. Sex-related differences in clinical presentation and outcome of transcatheter aortic valve implantation for severe aortic stenosis. J Am Coll Cardiol. 2012;59(6):566–71.PubMed
115.
Humphries KH, Toggweiler S, Rodes-Cabau J, Nombela-Franco L, Dumont E, Wood DA, et al. Sex differences in mortality after transcatheter aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol. 2012;60(10):882–6.PubMed
116.
Zhao ZG, Liao YB, Peng Y, Chai H, Liu W, Li Q, et al. Sex-related differences in outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2013;6(5):543–51.PubMed
117.
Szerlip M, Gualano S, Holper E, Squiers JJ, White JM, Doshi D, et al. Sex-specific outcomes of transcatheter aortic valve replacement with the SAPIEN 3 valve: insights from the PARTNER II S3 high-risk and intermediate-risk cohorts. JACC Cardiovasc Interv. 2018;11(1):13–20.PubMed
118.
Doshi R, Shlofmitz E, Meraj P. Comparison of outcomes and complications of transcatheter aortic valve implantation in women versus men (from the National Inpatient Sample). Am J Cardiol. 2018;121(1):73–7.PubMed
119.
O’Connor SA, Morice MC, Gilard M, Leon MB, Webb JG, Dvir D, et al. Revisiting sex equality with transcatheter aortic valve replacement outcomes: a collaborative, patient-level meta-analysis of 11,310 patients. J Am Coll Cardiol. 2015;66(3):221–8.PubMed
120.
Buellesfeld L, Stortecky S, Kalesan B, Gloekler S, Khattab AA, Nietlispach F, et al. Aortic root dimensions among patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2013;6(1):72–83.PubMed
121.
Ribeiro HB, Webb JG, Makkar RR, Cohen MG, Kapadia SR, Kodali S, et al. Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. J Am Coll Cardiol. 2013;62(17):1552–62.PubMed
122.
Cao D, Chiarito M, Pagnotta P, Reimers B, Stefanini GG. Coronary revascularisation in transcatheter aortic valve implantation candidates: why, who, when? Interv Cardiol. 2018;13(2):69–76.PubMedPubMedCentral
123.
Witberg G, Regev E, Chen S, Assali A, Barbash IM, Planer D, et al. The prognostic effects of coronary disease severity and completeness of revascularization on mortality in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10(14):1428–35.PubMed
124.
Sankaramangalam K, Banerjee K, Kandregula K, Mohananey D, Parashar A, Jones BM, et al. Impact of coronary artery disease on 30-day and 1-year mortality in patients undergoing transcatheter aortic valve replacement: a meta-analysis. J Am Heart Assoc. 2017;6(10):e006092.PubMedPubMedCentral
125.
Dewey TM, Brown DL, Herbert MA, Culica D, Smith CR, Leon MB, et al. Effect of concomitant coronary artery disease on procedural and late outcomes of transcatheter aortic valve implantation. Ann Thorac Surg. 2010;89(3):758–67 (Discussion 67).PubMed
126.
Faroux L, Guimaraes L, Wintzer-Wehekind J, Junquera L, Ferreira-Neto AN, Del Val D, et al. Coronary artery disease and transcatheter aortic valve replacement: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(3):362–72.PubMed
127.
Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010;121(13):e266–369.PubMed
Metadata
Title
Expansion of TAVR into Low-Risk Patients and Who to Consider for SAVR
Authors
Kunal V. Patel
Wally Omar
Pedro Engel Gonzalez
Michael E. Jessen
Lynn Huffman
Dharam J. Kumbhani
Anthony A. Bavry
Publication date
01-12-2020
Publisher
Springer Healthcare
Published in
Cardiology and Therapy / Issue 2/2020
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-020-00198-z

Other articles of this Issue 2/2020

Cardiology and Therapy 2/2020 Go to the issue

Original Research

The Effect of Low-Dose Ticagrelor on Platelet Function Profiles in Patients With Stable Coronary Artery Disease in Trinidad: The TWIST Pilot Study

Commentary

A Call for a New Paradigm for Diabetes Care in the Era of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i)

Review

Hypochloraemia in Patients with Heart Failure: Causes and Consequences

Review

Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials

Commentary

Anatomical Extent of Venous Reflux

Brief Report

Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits